全文获取类型
收费全文 | 2539252篇 |
免费 | 183864篇 |
国内免费 | 3866篇 |
专业分类
耳鼻咽喉 | 35489篇 |
儿科学 | 82979篇 |
妇产科学 | 68327篇 |
基础医学 | 374089篇 |
口腔科学 | 69812篇 |
临床医学 | 225563篇 |
内科学 | 493453篇 |
皮肤病学 | 58165篇 |
神经病学 | 202418篇 |
特种医学 | 96542篇 |
外国民族医学 | 538篇 |
外科学 | 383811篇 |
综合类 | 48773篇 |
现状与发展 | 12篇 |
一般理论 | 900篇 |
预防医学 | 194957篇 |
眼科学 | 59111篇 |
药学 | 189221篇 |
9篇 | |
中国医学 | 4941篇 |
肿瘤学 | 137872篇 |
出版年
2021年 | 19990篇 |
2019年 | 22687篇 |
2018年 | 31662篇 |
2017年 | 23761篇 |
2016年 | 26911篇 |
2015年 | 30162篇 |
2014年 | 41624篇 |
2013年 | 61692篇 |
2012年 | 86373篇 |
2011年 | 90898篇 |
2010年 | 53790篇 |
2009年 | 50412篇 |
2008年 | 84953篇 |
2007年 | 90616篇 |
2006年 | 91386篇 |
2005年 | 89207篇 |
2004年 | 85066篇 |
2003年 | 81914篇 |
2002年 | 79252篇 |
2001年 | 113907篇 |
2000年 | 116502篇 |
1999年 | 97657篇 |
1998年 | 27076篇 |
1997年 | 23363篇 |
1996年 | 23456篇 |
1995年 | 23543篇 |
1994年 | 21633篇 |
1993年 | 20414篇 |
1992年 | 74226篇 |
1991年 | 72429篇 |
1990年 | 70659篇 |
1989年 | 67827篇 |
1988年 | 62198篇 |
1987年 | 61036篇 |
1986年 | 57005篇 |
1985年 | 54713篇 |
1984年 | 40618篇 |
1983年 | 34482篇 |
1982年 | 20577篇 |
1979年 | 37224篇 |
1978年 | 26631篇 |
1977年 | 22064篇 |
1976年 | 21074篇 |
1975年 | 22905篇 |
1974年 | 27321篇 |
1973年 | 25964篇 |
1972年 | 24324篇 |
1971年 | 23103篇 |
1970年 | 21253篇 |
1969年 | 20236篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
51.
Malinin Oleg V. Kiryanov Nikolay A. 《European journal of clinical microbiology & infectious diseases》2022,41(7):1059-1064
European Journal of Clinical Microbiology & Infectious Diseases - Hemorrhagic fever with renal syndrome (HFRS) continues to be a cause of death in Europe. Our aim was to describe the clinical... 相似文献
52.
53.
54.
Hendrik Kröning Thomas Göhler Thomas Decker Marc Grundeis Georgi Kojouharoff Jörg Lipke Dieter Semsek Enno Moorahrend Annette Sauer Harald-Robert Bruch Rüdiger Liersch Arnd Nusch Ursula Vehling-Kaiser Manfred Welslau Ralf Grunewald Hanns-Detlev Harich Marcel Stephany Jens Uhlig Rebecca de Buhr Melanie Frank Cathrin Hogrefe Norbert Marschner Karin Potthoff Frank Hartmann Timo Reisländer Ingo Schwaner 《International journal of cancer. Journal international du cancer》2023,153(6):1227-1240
The prospective, multicenter, noninterventional TACTIC study assessed effectiveness and safety of trifluridine/tipiracil (FTD/TPI) in patients with metastatic colorectal cancer (mCRC) in a real-world setting in Germany, thus evaluating the external validity of the findings from the pivotal RECOURSE trial. Primary endpoint was overall survival (OS). Secondary objectives included progression-free survival (PFS), safety, and quality of life (QoL). Subgroups comprised patients with good (<3 metastatic sites at inclusion, ≥18 months from diagnosis of first metastasis to inclusion) or poor (remaining patients) prognostic characteristics (GPC/PPC). GPC without liver metastases was considered best prognostic characteristics (BPC). In total, 307 eligible patients (pretreated or not suitable for other available therapies) were treated with FTD/TPI. Overall, median [95%-CI] OS was 7.4 months [6.4-8.6], median PFS was 2.9 months [2.8-3.3]. In BPC (n = 65) and GPC (n = 176) compared to PPC (n = 124) subgroup, median OS (13.3 [9.1-17.6] vs 8.9 [7.6-9.8] vs 5.1 [4.4-7.0] months) and median PFS (4.0 [3.3-5.3] vs 3.4 [3.0-3.7] vs 2.6 [2.4-2.8] months) were longer. Patient-reported QoL, assessed by validated questionnaires (EQ-5D-5L, PRO-CTCAE), was stable throughout FTD/TPI treatment. Predominant FTD/TPI-related adverse events of grades 3 or 4 were neutropenia (13.0%), leukopenia (7.5%), and anemia (5.2%). Altogether, palliative FTD/TPI therapy in patients with pretreated mCRC was associated with prolonged survival, delayed progression, maintained health-related QoL, and manageable toxicity. Low metastatic burden and indolent disease were favorable prognostic factors for survival. TACTIC confirms the effectiveness and safety of FTD/TPI, highlighting its value in routine clinical practice. 相似文献
55.
Thomas Fuchs-Buder Sorin J. Brull Malin Jonsson Fagerlund J. Ross Renew Guy Cammu Glenn S. Murphy Michiel Warlé Matias Vested Béla Fülesdi Reka Nemes Malachy O. Columb Daniela Damian Peter J. Davis Hajime Iwasaki Lars I. Eriksson 《Acta anaesthesiologica Scandinavica》2023,67(8):994-1017
The set of guidelines for good clinical research practice in pharmacodynamic studies of neuromuscular blocking agents was developed following an international consensus conference in Copenhagen in 1996 (Viby-Mogensen et al., Acta Anaesthesiol Scand 1996, 40 , 59–74); the guidelines were later revised and updated following the second consensus conference in Stockholm in 2005 (Fuchs-Buder et al., Acta Anaesthesiol Scand 2007, 51 , 789–808). In view of new devices and further development of monitoring technologies that emerged since then, (e.g., electromyography, three-dimensional acceleromyography, kinemyography) as well as novel compounds (e.g., sugammadex) a review and update of these recommendations became necessary. The intent of these revised guidelines is to continue to help clinical researchers to conduct high-quality work and advance the field by enhancing the standards, consistency, and comparability of clinical studies. There is growing awareness of the importance of consensus-based reporting standards in clinical trials and observational studies. Such global initiatives are necessary in order to minimize heterogeneous and inadequate data reporting and to improve clarity and comparability between different studies and study cohorts. Variations in definitions of endpoints or outcome variables can introduce confusion and difficulties in interpretation of data, but more importantly, it may preclude building of an adequate body of evidence to achieve reliable conclusions and recommendations. Clinical research in neuromuscular pharmacology and physiology is no exception. 相似文献
56.
Bartz Hans-Jürgen 《Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz》2022,65(3):293-301
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz - Das klinische Risikomanagement (kRM) unterstützt Mitarbeitende im Gesundheitswesen dabei, Risiken bei der... 相似文献
57.
Troppmair Teresa Egger J. Krösbacher A. Zanvettor A. Schinnerl A. Neumayr A. Baubin M. 《Der Anaesthesist》2022,71(4):272-280
Die Anaesthesiologie - Die Qualität eines Rettungssystems zeichnet sich auch durch den effizienten Einsatz seiner personellen und Fahrzeugressourcen aus. So können im berechtigten Fall... 相似文献
58.
Evaluation of the Role of Merromoside from Ipomoea aquatica Forsskal Hydroalcoholic Extract in the Downregulation of ROS Species in Overcoming MDR in Breast Cancer 下载免费PDF全文
Sasikala MMohan SSwarnakumari SNagarajan A 《Asian Pacific journal of cancer prevention》2022,23(11):3657-3663
Purpose: The medicinal plant Ipomoea aquatica belonging to convulvulaceae family is an effective natural herb for treatment of various ailments and possesses effective anticancer activity. The aim of the work is to characterize a secondary metabolite merromoside (a resin glycoside) for anti-breast cancer activity through down regulation of ROS species. Methods: The Extract of the whole plant has been prepared by maceration method using 50%v/v ethanol in distilled water to get a hydroalcoholic extract. The phytochemical evaluation reveals that the active secondary metabolite was isolated by using column chromatographic technique. The isolated compound was evaluated for its anticancer properties through invitro method such as 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay on Michigan Cancer Foundation-7 Cell lines. The purity and structural characterization were done by high-performance thin layer chromatography, Fourier Transform Infrared Spectroscopy, Proton and13C Nuclear Magnetic Resonance spectroscopy and Liquid Chromatography–Mass Spectrometry. Results: The isolated compound (W04) from the derived extract showed Rf value of 0.79 that showed IC50 of 182.8μg/ml. The chemical structure of W04 has been confirmed as [4,5-dihydroxy-6-[5-hydroxy-2-methyl-4-(2-methylpropanoyloxy)-6-[(24,25,26-trihydroxy-5,23-dimethyl-9-oxo-19-pentyl-2,4,8,20,22-pentaoxatricyclo[19.2.2.13,7]hexacosan-6-yl)oxy]oxan-3-yl]oxy-2-methyloxan-3-yl] 2-methyl propanoate with the molecular weight of 979.15268. The isolated compound merromoside from hydroalcoholic extract of Ipomoea aquatica has been evaluated for anti-breast cancer properties. The down regulation of ROS species will prevent reverse signalling and angiogenesis. This indicates that merromoside will overcome MDR in breast cancer especially DOX-resistant. 相似文献
59.